Sponsored by

Poster Number Index
Click on one of the following number ranges below to display a list of posters.
Click the checkbox next to each item to bookmark.

101 – 200 | 201 – 300 | 301 – 400 | 401 – 500 | 501 – 600 | 601 – 700 | 701 – 800
801 – 900 | 901 – 1000 | 1001 – 1100 | 1101 – 1200 | 2001 – 2100 | 2101 – 2200 | 3001 – 3100
3101 – 3200 | 4001 – 4100 | 4101 – 4200 | 5001 – 5100 | 5101 – 5200 | 6001 – 6100 | 6101 – 6152

  [2101] Development and evaluation of a cancer risk educational tool (CREdIT) for women with a family history of breast and ovarian cancer.
  [2102] Understanding of breast cancer concepts in an undereducated county hospital population.
  [2103] Assessment of barriers to patient participation in clinical trials among oncology outpatients at a community teaching hospital in Toronto.
  [2104] Awareness of breast cancer among women in an urban region of China.
  [2105] The use of a mixed reality breast simulator with an innovative touch map feedback system to teach breast history-taking and examination skills.
  [2106] A 24-month subgroup analysis of the effect of denosumab on bone mineral density in women with breast cancer undergoing aromatase inhibitor therapy.
  [2109] Tolerability of lapatinib given concurrently with paclitaxel and trastuzumab as part of adjuvant therapy in patients with resected HER2+ breast cancer: initial safety data from the Mayo Clinic cancer research consortium trial RC0639.
  [2110] A pilot study of adjuvant doxorubicin and cyclophosphamide followed by paclitaxel plus sorafenib in women with node positive or high-risk breast cancer.
  [2111] Preliminary toxicity results of a phase II trial of adjuvant docetaxel/cyclophosphamide plus trastuzumab in HER2+ early stage breast cancer patients.
  [2112] Cost-effectiveness of zoledronic acid plus endocrine therapy in premenopausal women with early stage breast cancer based on results of the ABCSG-12 study.
  [2113] The number needed to treat (NNT) as a measure of drug efficacy: the case of zoledronic acid for early hormone-responsive breast cancer in the ABCSG-12 trial.
  [2116] The mechanism of Astragalus membranaceus' effects on the proliferation of human basal-like breast cancer cell line MDA-MB-468 from p53/MDM2 pathway.
  [2117] Adjuvant therapy decisions in breast cancer: comparison of a multi disciplinary team's decisions with the recommendations of web-based computer programme “Adjuvant Online”.
  [2119] Targeting of breast cancer with non-oncology drugs – possible novel therapeutic option for triple-negative breast cancer.
  [2120] Triple negative breast cancer: a phase 2, multi-center, open-label, randomized trial of gemcitabine/carboplatin (G/C), with or without BSI-201, a PARP inhibitor.
  [2121] Combination or sequential single agent for the treatment of metastatic breast cancer (MBC) patients (pts). Impact of further chemotherapy (CT) in overall survival (OS) in the Alamo registry.
  [2122] Ispinesib (SB-715992) a kinesin spindle protein (KSP) inhibitor has single agent activity and enhances the efficacy of standard-of-care therapies in pre-clinical models of breast cancer.
  [2124] Direct tumor targeting using nanobioconjugate with a combination of monoclonal antibodies for breast cancer treatment.
  [2127] Role of the prostaglandin receptor EP3 in regulating vasculogenic mimicry of inflammatory breast cancer.
  [2130] Effects of the combined blockade of EGFR and ErbB-2 on signal transduction and regulation of cell cycle regulatory proteins in breast cancer cells.
  [2131] A multi-center phase II study of three doses of TAS-108 in postmenopausal women with advanced breast carcinoma following first or second line endocrine therapy.
  [2132] A phase II, randomized, open-label, dose-finding study of TAS-108, a novel steroidal antiestrogen, administered orally in postmenopausal women with advanced or metastatic breast cancer.
  [2133] Effects of novel retinoic acid metabolism blocking agent (VN/14-1) on N-methyl-N-nitrosourea (MNU)-induced mammary carcinoma and uterus in the rat model.
  [2134] Internalization and retention of nanodiamonds by MCF-7 cells in vitro: a potential drug delivery platform.
  [2135] Reduction of chemotherapy side effects and targeted inhibition of lymph node metastasis with a calcium phosphate nanoparticle delivery vehicle.
  [2136] Safety of the anti-IGF-1R antibody CP-751,871 in combination with exemestane in patients with advanced breast cancer.
  [2142] The taccalonolides are a novel class of microtubule stabilizers that circumvent clinically relevant taxane resistance mechanisms.
  [2145] Induction of apoptosis in vitro and in vivo effects of a synthetic nitroflavone derivative on murine mammary adenocarcinoma cells.
  [2146] Development of a targeted topoisomerase I inhibitor for anticancer therapy.
  [2148] A phase I-II trial of Ispinesib, a kinesin spindle protein inhibitor, dosed every two weeks in patients with locally advanced or metastatic breast cancer previously untreated with chemotherapy for metastatic disease or recurrence.
  [2149] Drug efflux by breast cancer resistance protein (BCRP) is a mechanism of resistance to the insulin-like growth factor receptor/insulin receptor inhibitor, BMS-536924.
  [2150] In vivo activity of ARRY-543, a potent, small molecule inhibitor of EGFR/ErbB-2 in combination with trastuzumab or docetaxel.
  [2151] Evaluation of the molecular mechanisms for the sequence-dependent, synergistic anti-tumour effects of doxorubicin and zoledronic acid in breast cancer.
  [2152] Autologous dendritic cell vaccine directed at wild type p53 in patients with high-risk breast cancer treated with adjuvant chemotherapy.
  [2153] Transcriptional gene expression profiles indicate response of breast cancer cell lines to aminoflavone prodrug.
  [2155] Docetaxel and carboplatin followed by sequential capecitabine as first line treatment in patients with locally advanced or metastatic breast cancer.
  [2156] N-ethoxybenzylimidazoles: a novel acid-sensitive linker for controlled release of therapeutics from drug delivery systems.
  [2157] The safety of dose-dense liposomal-encapsulated doxorubicin in association with docetaxel (MyTax) in breast cancer.
  [2158] Novel thermal tumor ablation for breast cancer in mice using magnetic nanoparticles.
  [2159] Immunotherapy following high-dose chemotherapy (HDCT) and peripheral blood progenitor cell transplantation (PBPCT) in the treatment of high-risk early breast cancer (HREBC) and metastatic breast cancer (MBC).
  [2160] A multistage nanodelivery system for therapeutic applications and medical imaging: in vivo biodistribution and efficacy study in a murine orthotopic breast cancer model.

 
 

Poster Sessions | Support | FAQ | Privacy Policy

San Antonio Breast Cancer Symposium
7703 Floyd Curl Dr. Mail Code 8224
San Antonio, TX 78229 USA
http://www.sabcs.org
Technical Support • © 2010 Marathon Multimedia, a Learner’s Digest International business. • All rights reserved